Ralf Gold

Research interests

Publications

• Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

  Journal of Neurology · 2023 · https://doi.org/10.1007/s00415-023-11910-z

• Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

  Neurology Neuroimmunology & Neuroinflammation · 2021 · https://doi.org/10.1212/nxi.0000000000001100

• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30475-6

• Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.09.049

• ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

  Multiple Sclerosis Journal · 2018 · https://doi.org/10.1177/1352458517751049

• ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis

  European Journal of Neurology · 2018 · https://doi.org/10.1111/ene.13536

• DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-04732-5

• Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

  Journal of Neurology · 2016 · https://doi.org/10.1007/s00415-016-8045-z

• MS disease activity in RESTORE

  Neurology · 2014 · https://doi.org/10.1212/wnl.0000000000000355

• Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

  The Lancet · 2013 · https://doi.org/10.1016/s0140-6736(12)62190-4

• Leitlinien für Diagnostik und Therapie in der Neurologie

  Journal · 2012 · https://doi.org/10.1055/b-002-37755

• Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1114287

• Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

  Multiple Sclerosis Journal · 2012 · https://doi.org/10.1177/1352458511435105

• Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)60918-6

• Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61619-0

• Tumor Recurrence and Survival in Patients Treated for Thymomas and Thymic Squamous Cell Carcinomas: A Retrospective Analysis

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.10.113

• Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

  PubMed · 1994

Current projects

No projects listed.